Search

Your search keyword '"Michael D. Ezekowitz"' showing total 3 results
Start Over Author "Michael D. Ezekowitz" Publication Year Range Last 3 years
3 results on '"Michael D. Ezekowitz"'

1. The ATHERO-AF Study

Author

Michael D. Ezekowitz, MBChB, DPhil, Ibrahim Alameh, MD, and Mohammed Kamareddine, MD

Subjects
atrial fibrillation, direct-oral anticoagulants, drug interactions, Diseases of the circulatory (Cardiovascular) system, RC666-701, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Published
2024
Full Text
View/download PDF

2. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant

Author

Roy Taoutel, Michael D. Ezekowitz, Usman A. Chaudhry, Carly Weber, Dana Hassan, Ed J. Gracely, Mohammed H. Kamareddine, Benjamin I. Horn, and Glenn R. Harper

Subjects
Atrial fibrillation, Direct-acting oral anticoagulants, DOAC, Elderly, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Direct-acting oral anticoagulants (DOACs) represent the standard for preventing stroke and systemic embolization (SSE) in patients with atrial fibrillation (AF). There is limited information for patients ≥ 80 years. We report a retrospective analysis of AF patients ≥ 80 years prescribed either a US Food and Drug Administration (FDA)-approved reduced (n = 514) or full dose (n = 199) DOAC (Dabigatran, Rivaroxaban, or Apixaban) between January 1st, 2011 (first DOAC commercially available) and May 31st, 2017. The following multivariable differences in baseline characteristics were identified: patients prescribed a reduced dose DOAC were older (p

Published
2022
Full Text
View/download PDF

3. Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation

Author

Matthew A. Carlisle, Peter Shrader, Marat Fudim, Karen S. Pieper, Rosalia G. Blanco, Gregg C. Fonarow, Gerald V. Naccarelli, Bernard J. Gersh, James A. Reiffel, Peter R. Kowey, Benjamin A. Steinberg, James V. Freeman, Michael D. Ezekowitz, Daniel E. Singer, Larry A. Allen, Paul S. Chan, Sean D. Pokorney, Eric D. Peterson, and Jonathan P. Piccini

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Oral anticoagulation (OAC) reduces the risk of thromboembolic events in patients with atrial fibrillation (AF); however, thromboembolism (TE) still can occur despite OAC. Factors associated with residual risk for stroke, systemic embolism, or transient ischemic attack events despite OAC have not been well described.The purpose of this study was to evaluate the residual risk of thromboembolic events in patients with AF despite OAC.A total of 18,955 patients were analyzed in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I and II) using multivariable Cox proportional hazard modeling. Mean age was 72 ± 10.7, and 42% were women. There were 451 outcome events.The risk of TE despite OAC increased with CHAPatients with AF have a residual risk of TE with increasing CHA

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results